Compare SHIM & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHIM | KRRO |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.8M | 187.9M |
| IPO Year | 2023 | 2019 |
| Metric | SHIM | KRRO |
|---|---|---|
| Price | $3.35 | $14.22 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $34.80 |
| AVG Volume (30 Days) | ★ 157.6K | 90.5K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.95 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $492,844,000.00 | $6,392,000.00 |
| Revenue This Year | $13.99 | N/A |
| Revenue Next Year | $6.94 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.63 | ★ 181.46 |
| 52 Week Low | $1.95 | $5.20 |
| 52 Week High | $6.76 | $55.89 |
| Indicator | SHIM | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 39.11 | 60.41 |
| Support Level | $2.49 | $9.76 |
| Resistance Level | $4.09 | $14.42 |
| Average True Range (ATR) | 0.26 | 0.95 |
| MACD | -0.04 | 0.12 |
| Stochastic Oscillator | 14.04 | 71.95 |
Shimmick Corp is engaged in delivering turnkey infrastructure solutions that strengthen critical markets across water, energy, climate resiliency, and sustainable transportation. It selectively focuses on the following types of infrastructure projects: Water Treatment, Water Resources, and Other Critical Infrastructure. In water treatment projects the company expands, rehabilitates, upgrades, builds and rebuilds water and wastewater treatment infrastructure. In Other Critical Infrastructure projects, It builds, retrofits, expands, rehabilitates, operates, and maintains critical infrastructure, including mass transit, bridges, and military infrastructure. The company has one operating and reportable segment: infrastructure solutions. All of its revenue is derived from the United States.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.